What is Precision Epigenomics?
Precision Epigenomics is at the forefront of revolutionizing healthcare through innovative technology designed for the early detection of multiple cancer types via a simple liquid biopsy. The company's EPISEEK tests are engineered for speed, accuracy, and affordability, aiming to provide patients with crucial peace of mind regarding their health. Precision Epigenomics operates with a mission to enhance well-being, positioning itself as a key player in the diagnostic and precision medicine landscape.
How much funding has Precision Epigenomics raised?
Precision Epigenomics has raised a total of $4.2M across 3 funding rounds:
Other Financing Round
$2.4M
Series A
$1.5M
Debt
$265K
Series A (2024): $1.5M with participation from Shaffer Capital
Other Financing Round (2024): $2.4M, investors not publicly disclosed
Debt (2025): $265K, investors not publicly disclosed
Key Investors in Precision Epigenomics
Shaffer Capital
Shaffer Capital is an investment firm focused on providing comprehensive financial planning and management services. Their expertise likely extends to strategic investments in companies with strong growth potential, particularly within sectors that require significant capital for innovation and market expansion.
What's next for Precision Epigenomics?
With the recent influx of major strategic investment and substantial enterprise-level funding, Precision Epigenomics is poised for significant expansion. The company is likely to channel these resources into scaling its operational capacity, enhancing its research and development pipeline for new diagnostic markers, and broadening its market reach. This strategic financing will also support efforts to further validate the efficacy and cost-effectiveness of its EPISEEK tests, solidifying its position as a leader in early cancer detection and contributing to improved patient outcomes globally.
See full Precision Epigenomics company page
